Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs

J Vet Pharmacol Ther. 2004 Oct;27(5):369-72. doi: 10.1111/j.1365-2885.2004.00582.x.

Authors

L J Smith¹, L Krugner-Higby, L A Trepanier, D E Flaska, V Joers, T D Heath

Affiliation

¹ Department of Surgical Sciences, School of Veterinary, University of Wisconsin, 2015 Linden Drive, Madison, WI 53706, USA. smith@svm.vetmed.wisc.edu

PMID: 15500576
DOI: 10.1111/j.1365-2885.2004.00582.x

No abstract available

Publication types

Clinical Trial
Controlled Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Analgesics, Opioid / administration & dosage
Analgesics, Opioid / blood
Analgesics, Opioid / pharmacokinetics*
Analgesics, Opioid / pharmacology
Animals
Dogs / metabolism*
Dogs / physiology
Dose-Response Relationship, Drug
Drug Carriers / administration & dosage
Female
Heart Rate / drug effects
Hypnotics and Sedatives / administration & dosage
Hypnotics and Sedatives / blood
Hypnotics and Sedatives / pharmacokinetics*
Hypnotics and Sedatives / pharmacology
Injections, Subcutaneous / veterinary
Liposomes / administration & dosage
Male
Oxymorphone / administration & dosage
Oxymorphone / blood
Oxymorphone / pharmacokinetics*
Oxymorphone / pharmacology
Respiration / drug effects

Substances

Analgesics, Opioid
Drug Carriers
Hypnotics and Sedatives
Liposomes
Oxymorphone